|1.||Heberer, Michael: 4 articles (03/2010 - 01/2004)|
|2.||Spagnoli, Giulio C: 4 articles (03/2010 - 01/2004)|
|3.||Rosenthal, Rachel: 3 articles (03/2010 - 12/2005)|
|4.||Adamina, Michel: 3 articles (03/2010 - 01/2004)|
|5.||Zajac, Paul: 3 articles (03/2010 - 01/2004)|
|6.||Ito, M: 3 articles (10/2001 - 11/2000)|
|7.||Itoh, K: 3 articles (10/2001 - 11/2000)|
|8.||Oertli, Daniel: 2 articles (03/2010 - 12/2005)|
|9.||Bolli, Martin: 2 articles (03/2010 - 01/2004)|
|10.||Weber, Walter P: 2 articles (03/2010 - 12/2005)|
07/01/2006 - "These CTLs were able to lyse HLA-A0201 expressing target cells that were pulsed with peptide, and more importantly, were effective in killing tumor cells that express PAX3, including ERMS, ES and MEL cell lines. "
01/01/2013 - "The dominance of EBNA1(562-570) in association with HLA-A0201 was consistently observed in cell lines and EBV-associated tumor biopsies. "
11/01/2012 - "In contrast, the activated CTL could neither kill the hTERT-negative tumor cells, such as U2OS cells, nor kill HLA-A0201 negative cells, such as HepG2 cells. "
07/01/2006 - "These findings provide compelling evidence that peptide PAX3-282 is naturally processed by tumors and is presented in the context of HLA-A0201 in adequate amounts to allow CTL recognition. "
05/01/1999 - "HLA-A0201, HLA-A0206 and HLA-A0207 tumor cells were lysed by the HLA-A2-restricted CTL. "
|2.||Melanoma (Melanoma, Malignant)
09/01/2011 - "CTL lines, from 13 normal donors and 10 melanoma patients, all of whom were HLA-A0201 positive, were generated against the PRAME peptide epitope PRA(100-108). "
12/01/2005 - "These effector cells were able to efficiently kill HBL melanoma cells expressing Melan-A/MART-1 and HLA-A0201. "
01/26/2004 - "Powerful adjuvant effects of IRIV were also observed in the induction of CTL specific for the melanoma associated Melan-A/MART-1(27-35), HLA-A0201 restricted epitope. "
03/01/2010 - "We used a rVV encoding gp100(280-288), Melan-A/MART-1(27-35) and tyrosinase(1-9) HLA-A0201 restricted epitopes and CD80 and CD86 costimulatory molecules in stage III and IV melanoma patients in a phase 1/2 trial. "
12/01/2005 - "Efficient induction of tumoricidal cytotoxic T lymphocytes by HLA-A0201 restricted, melanoma associated, L(27)Melan-A/MART-1(26-35) peptide encapsulated into virosomes in vitro."
|3.||Human Influenza (Influenza)
06/01/1992 - "Recent reports suggest there is no interspecies recognition between CD8 and MHC class I. In this study, hybrid genes from human class I HLA-A0201 and murine class I H-2Kb were transfected into human and mouse cells and tested in Cr-release assays using HLA-A0201-restricted influenza A matrix peptide-specific CTL as effectors. "
12/01/1999 - "Generation of the HLA-A0201 (A2) influenza Matrix 58-66 epitope contained within the full-length Matrix protein is impaired in cells lacking the proteasome subunits low molecular protein 2 (LMP2) and LMP7. "
01/01/1995 - "After influenza A infection, a peptide from the matrix protein, M58-66, is presented in the context of the MHC allele HLA-A0201 and the resulting CTL response is detectable in most HLA-A0201 subjects. "
|5.||Chronic Hepatitis B
|4.||Complementary DNA (cDNA)
|6.||Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF)
|7.||HLA-A2 Antigen (HLA A2 Antigen)
|8.||Proteasome Endopeptidase Complex (Proteasome)
|10.||Interleukin-4 (Interleukin 4)